Share |
13 December 2017

Movers & Shakers

Meet Dario Rahelic, new IDF Europe Board Member from Croatia

Dr Dario Rahelic is a physician, internal medicine specialist, endocrinologist and diabetologist who has been engaged in daily clinical practice for 13 years.

DarioHe is assistant professor and Head of Department of Endocrinology, Diabetes and Metabolic Disorders at Dubrava University Hospital, Zagreb, Croatia, and is President of the Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association. He also serves as Executive commitee member of the Diabetes and Nutrition Study Group of EASD, the Croatian Endocrine Society, the Croatian Society for Obesity and the Croatian Society for Endocrine Oncology.

Dr Rahelic published several chapters in national and international books, articles in scientific journals and was invited speaker at many national and international conferences. His teaching enagements are at the Faculty of Medicine, the Faculty of Food Technology and Biotechnology and the Faculty of Pharmacy and Biochemistry. He was visiting scientist at St. Michael's Hospital in Toronto (Canada), Mayo Clinic in Rochester (USA) and Motol Clinic, Prague (Czech Republic).

Dr. Rahelic is a Fellow of the American College of Endocrinology and of the Royal College of Physicians of Edinburg. He received awards from the Diabetes and Nutrition Study Group of EASD, from the Croatian Endocrine Society, and the Etzwiller Rising Star Award.

As President of the Croatian Society for Diabetes and Metabolic Disorders, Dario Rahelic participated in negotiations with the Ministry of health of the Republic of Croatia, the Croatian national insurance company and other authorities to achieve better care for people with diabetes in Croatia. Recently, the Croatian Society for Diabetes and Metabolic Disorders together with Croatian Diabetes Association, a patient organization, achieved the full reimbursement by the national insurance company of one hundered insulin pumps per year. Futhermore, modern basal insulin analogues are now available for people with type 2 diabetes in basal oral therapy with reasonable co-payment. Most recently, the number of annual fully reimbursed test strips for the paediatric population incresased from 2'000 to 2'500.

Dr Rahelic's activities concentrate on improved access to modern diabetes treatment, improvement in patient education, involvement in parliamentary and other decision-making discussions, but mostly on improving the quality of life for people with diabetes. He believes that motivating people with diabetes to manage their condition is more effective than only talking about possible complications.

Dr Rahelic strongly believes in IDF Europe's clear mission and vision, and is honoured to be a member of its Board. He wishes to contribute to building awareness about diabetes and to advocate against discrimination; he hopes that this position will help him achieve better care for people with diabetes in his own country as well as in the region.